SCM
RLMD icon

Sterling Capital Management’s Relmada Therapeutics RLMD Stock Holding History

Sterling Capital Management’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.3K Buy
+332
New +$2.32K ﹤0.01% 2961

Other funds holding RLMD

PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
AW
Apricus Wealth Beaufort, South Carolina $210M AUM 30.06% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
ACA
American Capital Advisory Ketchum, Idaho $275M AUM 22.21% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Sterling Capital Management's RLMD Position: Q2 2026 in Review

Sterling Capital Management opened a new position in Relmada Therapeutics (RLMD) in Q2 2026: 332 shares worth $2.3K. The stake represents ﹤0.01% of the portfolio and ranks #2961 among its holdings.

9 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Sterling Capital Management held 332 shares of Relmada Therapeutics worth $2.3K as of Q2 2026.
  • Relmada Therapeutics was a new Sterling Capital Management position in Q2 2026.
  • Relmada Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2961 holding.
  • 9 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.